Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer

被引:5
|
作者
Harada, Toshiyuki [1 ]
Imai, Hisao [2 ,3 ]
Fumita, Soichi [4 ]
Noriyuki, Toshio [5 ]
Gamoh, Makio [6 ]
Okamoto, Masaharu [7 ]
Akashi, Yusaku [4 ]
Kizawa, Yoshiyuki [8 ]
Tokoro, Akihiro [9 ,10 ]
机构
[1] JCHO Hokkaido Hosp, Ctr Resp Dis, Sapporo, Hokkaido, Japan
[2] Gunma Prefectural Canc Ctr, Div Resp Med, Gunma, Japan
[3] Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[4] Kindai Univ, Dept Med Oncol, Nara Hosp, Nara, Japan
[5] Onomichi Gen Hosp, Dept Surg, Onomichi, Hiroshima, Japan
[6] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Miyagi, Japan
[7] Shionogi & Co Ltd, Med Affairs, Osaka, Japan
[8] Kobe Univ, Grad Sch Med, Dept Palliat Med, Kobe, Hyogo, Japan
[9] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Psychosomat Internal Med, Sakai, Osaka, Japan
[10] Natl Hosp Org Kinki Chuo Chest Med Ctr, Support & Palliat Care Team, Osaka, Japan
关键词
Cancer pain; GI cancer; Observational study; Opioid-induced constipation; OIC-J; VALIDATION; MANAGEMENT;
D O I
10.1007/s10147-020-01790-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Constipation is a common side effect of opioid therapy. An observational study of opioid-induced constipation (OIC) in Japanese patients with cancer (OIC-J) included 212 patients with various tumor types. This post hoc analysis of OIC-J evaluated a subgroup of patients with gastrointestinal (GI) cancer. Methods Patients were aged >= 20 years, starting strong opioid therapy, had an ECOG PS of <= 2, and must have had >= 3 bowel movements during the week before enrollment. OIC was evaluated for 2 weeks after opioid initiation using the Rome IV diagnostic criteria for colorectal disorders, as well as physician's diagnosis, number of spontaneous bowel movements, Bowel Function Index score, and patient's self-assessment. Relationships between baseline characteristics and OIC incidence, and the effects of OIC on quality of life (QOL) were also explored. Results Fifty patients from OIC-J who had GI cancer [colon (50%), stomach (28%), and esophageal (22%)] were included. OIC incidence varied by which diagnostic criteria were used (46.0-62.0%) and occurred rapidly after initiating opioid therapy. The use of prophylactic laxatives reduced the overall incidence rate of OIC from 71.0% to 47.4%. No baseline characteristics, except comorbidities, were associated with OIC incidence. Change from baseline to day 15 in PAC-SYM total score was significantly greater for patients with OIC versus those without OIC (0.188 versus -0.362;P = 0.0011). Conclusions This post hoc analysis suggests that OIC occurs rapidly in patients with GI cancer after initiating opioid therapy, and negatively impacts QOL. Early and effective intervention strategies may be particularly useful in this group. Additional Information Coauthor Makio Gamoh is deceased.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [11] Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
    Lemaire, Antoine
    Pointreau, Yoann
    Narciso, Berengere
    Piloquet, Francois-Xavier
    Braniste, Viorica
    Sabate, Jean-Marc
    SUPPORTIVE CARE IN CANCER, 2021, 29 (12) : 7577 - 7586
  • [12] Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
    Osaka, Iwao
    Ishiki, Niroto
    Yokota, Takaaki
    Tada, Yukio
    Sato, Hiroki
    Okamoto, Masaharu
    Satomi, Eriko
    ESMO OPEN, 2019, 4 (04)
  • [13] The Burden of Opioid-Induced Constipation in Younger Patients with Chronic Noncancer Pain
    Gupta, Anita
    Coyne, Karin S.
    Datto, Catherine
    Venuti, Christine
    PAIN MEDICINE, 2018, 19 (12) : 2459 - 2468
  • [14] Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study
    Mori, Masanori
    Ji, Yongli
    Kumar, Santosh
    Ashikaga, Takamaru
    Ades, Steven
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (02) : 397 - 404
  • [15] Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study
    Masanori Mori
    Yongli Ji
    Santosh Kumar
    Takamaru Ashikaga
    Steven Ades
    International Journal of Clinical Oncology, 2017, 22 : 397 - 404
  • [16] Opioid-induced Neurotoxicity in Patients with Cancer Pain
    Sebastiano Mercadante
    Current Treatment Options in Oncology, 2023, 24 : 1367 - 1377
  • [17] Opioid-induced Neurotoxicity in Patients with Cancer Pain
    Mercadante, Sebastiano
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1367 - 1377
  • [18] A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation-The NACASY Study
    Davies, Andrew
    Cinieri, Saverio
    Dupoiron, Denis
    Fernandez, Sofia Espana
    Leclerc, Johan
    Montesarchio, Vincenzo
    Mystakidou, Kyriaki
    Serna, Judith
    Tack, Jan
    CANCERS, 2022, 14 (05)
  • [19] Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study
    Imai, Hisao
    Fujita, Yukiyoshi
    Hiruta, Eriko
    Masuno, Takashi
    Yamazaki, Shigeki
    Tanaka, Hajime
    Kamiya, Teruhiko
    Sandoh, Mitsuru
    Takei, Satoshi
    Arai, Kazuya
    Nishiba, Hiromi
    Mogi, Junnosuke
    Koizuka, Shiro
    Saito, Taeko
    Obayashi, Kyoko
    Kaira, Kyoichi
    Minato, Koichi
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (05) : 571 - 577
  • [20] A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients
    Imai, Hisao
    Fujita, Yukiyoshi
    Hiruta, Eriko
    Masuno, Takashi
    Yamazaki, Shigeki
    Tanaka, Hajime
    Kamiya, Teruhiko
    Sandoh, Mitsuru
    Takei, Satoshi
    Arai, Kazuya
    Nishiba, Hiromi
    Mogi, Junnosuke
    Kaira, Kyoichi
    Minato, Koichi
    THORACIC CANCER, 2022, 13 (16) : 2301 - 2308